8 years ago

Nemesis Bioscience Secures £700k Seed Funding for Anti-Microbial Therapies

  • Nemesis Bioscience, a UK-based developer of products to resurrect anti-microbial therapies, raised over £700k in seed funding

  • The company intends to use the funds to validate its technologies.

      • ProblemHealthcare

      "making anti-microbial therapies effective again by countering increasing microbial resistance"

      Solution

      "developing Bacterial Cybergenetics technologies, including Nemesis Symbiotics to reverse antibiotic resistance and Transmids for clinical, veterinary, and industrial use"

      Covered on